Endogenous plasma riboflavin is not a viable BCRP biomarker in human
Clinical and Translational Science · 2024
DOI: 10.1111/cts.70109 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2024. Verfasst von John P Savaryn und 6 weiteren Autor:innen. Beteiligte Einrichtung: Quantitative, Translational and ADME Sciences, AbbVie Inc., North Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Riboflavin, ATP Binding Cassette Transporter, Subfamily G, Member 2, Drug Interactions, Neoplasm Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Recent reports suggest that plasma riboflavin may serve as a biomarker for BCRP inhibition in humans. However, the clinical data supporting this claim have been limited, with only two studies showing modest increases in riboflavin levels after administration of a BCRP inhibitor. We have recently demonstrated that co‐administration of 375 mg once daily (q.d.) cedirogant, an in vitro BCRP inhibitor, significantly increased rosuvastatin (an OATP1B1/1B3 and BCRP substrate) exposures but did not change the levels of the OATP1B endogenous biomarker coproporphyrin‐I, demonstrating that cedirogant is a clinical BCRP inhibitor. Samples from this same cedirogant clinical drug–drug interaction study were utilized to test the hypothesis that endogenous plasma riboflavin is a biomarker of BCRP inhibition. Plasma riboflavin levels in the absence of cedirogant ranged from 1 to 10 ng/mL across the 11 participants analyzed with minimal (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Quantitative, Translational and ADME Sciences, AbbVie Inc., North Chicago, Illinois, USA.
- Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA.
ORCID-Profile: Ryota Kikuchi, Yuli Qian, Mohamed-Eslam F Mohamed
Zitieren
APA
Savaryn, J. P., Kikuchi, R., Qian, Y., Ji, Q. C., Jenkins, G. J., Bow, D. A. J., & Mohamed, M. F. (2024). Endogenous plasma riboflavin is not a viable BCRP biomarker in human. Clinical and Translational Science. https://doi.org/10.1111/cts.70109
Vancouver
Savaryn JP, Kikuchi R, Qian Y, Ji QC, Jenkins GJ, Bow DAJ, et al. Endogenous plasma riboflavin is not a viable BCRP biomarker in human. Clinical and Translational Science. 2024. doi:10.1111/cts.70109
BibTeX
@article{Savaryn2024,
author = {Savaryn, John P and Kikuchi, Ryota and Qian, Yuli and Ji, Qin C and Jenkins, Gary J and Bow, Daniel A J and Mohamed, Mohamed-Eslam F},
title = {Endogenous plasma riboflavin is not a viable BCRP biomarker in human},
journal = {Clinical and Translational Science},
year = {2024},
doi = {10.1111/cts.70109}
}
EUVIMED